Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.
Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.
复制标题
DOI：
10.1530/eje-11-1068
复制
发表时间：
2012-04
影响因子：
5.8
通讯作者：
Miller KK
中科院分区：
文献类型：
--
作者：
Bredella MA;Lin E;Brick DJ;Gerweck AV;Harrington LM;Torriani M;Thomas BJ;Schoenfeld DA;Breggia A;Rosen CJ;Hemphill LC;Wu Z;Rifai N;Utz AL;Miller KK
腹部肥胖与心血管风险增加和生长激素（GH）分泌减少有关。本研究的目的是确定生长激素对腹型肥胖妇女的身体成分和心血管危险标志物的影响。在这项随机、双盲、安慰剂对照研究中，79名绝经前肥胖妇女接受GH与安慰剂治疗6个月。主要终点为：1）通过CT（身体成分）测量的腹部总脂肪（达特）和2）高敏C反应蛋白（hsCRP）（心血管风险标志物）。通过CT、DXA和质子MR波谱评估身体成分。检测血清心血管危险标志物、颈动脉内膜中层厚度和内皮功能。平均6个月GH剂量为1.7±0.1 mg/天，导致GH组的平均IGF-1 SDS从−1.7±0.08增加至−0.1±0.3。与安慰剂相比，GH给药降低达特和hsCRP。此外，与安慰剂相比，它增加了大腿肌肉质量和瘦体重，降低了皮下腹部和躯干脂肪、tPA、apoB和apoB/LDL。GH组内脏脂肪组织减少，IMCL增加。IGF-1水平的6个月变化与达特和VAT的6个月下降呈负相关。1例受试者在3个月时2小时葡萄糖>200 mg/mL; 4例受试者（其中3例随机分配至GH组）在研究结束时2小时葡萄糖水平>200 mg/mL。在腹部肥胖的绝经前妇女生长激素管理发挥有益的影响，身体成分和心血管风险标志物，但与少数妇女的葡萄糖耐量下降。
Abdominal adiposity is associated with increased cardiovascular risk and decreased growth hormone (GH) secretion. The objective of our study was to determine the effects of GH in abdominally obese women on body composition and cardiovascular risk markers. In this randomized, double-blind, placebo-controlled study, 79 obese premenopausal women received GH vs. placebo for six months. Primary endpoints were: 1) total abdominal (TAT) fat by CT (body composition) and 2) high-sensitivity C-reactive protein (hsCRP) (cardiovascular risk marker). Body composition was assessed by CT, DXA and proton MR spectroscopy. Serum cardiovascular risk markers, carotid intima-media thickness and endothelial function were measured. Mean 6-month GH dose was 1.7±0.1 mg/day, resulting in a mean IGF-1 SDS increase from −1.7±0.08 to −0.1±0.3 in the GH group. GH administration decreased TAT and hsCRP compared with placebo. In addition, it increased thigh muscle mass and lean body mass, and decreased subcutaneous abdominal and trunk fat, tPA, apoB, and apoB/LDL compared with placebo. Visceral adipose tissue decreased and IMCL increased within the GH group. Six-month change in IGF-1 levels was negatively associated with 6-month decrease in TAT and VAT. One subject had a 2-hour glucose >200 mg/mL at 3 months; four subjects, three of whom were randomized to GH, had 2-hour glucose levels >200 mg/mL at study end. GH administration in abdominally obese premenopausal women exerts beneficial effects on body composition and cardiovascular risk markers, but is associated with a decrease in glucose tolerance in a minority of women.